drugset / Trial / NCT07210320
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
Phase 1
Completed
32 enrolled
Insignis Therapeutics, Inc.
Washington University School of Medicine · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This is an open-label, three-part study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as a single dose of L-dipivefrin (IN-001) sublingual spray or drop in healthy adults. For all parts of the study, participants will undergo at least 10 hours of fasting prior to dosing. Part 1 of the study focuses on IN-001 dose/formulation exploration in a small number of participants (N=6); Part 2 of the study involving up to 12 participants will test a dose selected from Part 1 delivered as both a sublingual spray and a sublingual drop. In Part 3, one delivery method will be tested. Total number of participants is 30.
Timeline
- Start
- 2025-10-24
- Primary completion
- 2026-04-12
- Completion
- 2026-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Epinephrine | Other / unclassified | 0.3 mg | Intramuscular |
| Subject | L-dipivefrin | Unknown | 9.06 mg | Other |
| Subject | L-dipivefrin | Unknown | 13.59 mg | Other |